Press

Releases

HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced the pricing of its underwritten public offering of approximately 24,228,719 shares of its common stock for gross

HOUSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it has commenced an underwritten public offering of its common stock.

Presented early data highlighting first successful objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON) Actively enrolling patients in TCR-T Library Phase 1/2 trial at the

HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, before the open of U.S. markets.

Data supports high-throughput screening process to identify neoantigen-reactive TCRs Exclusive ownership of discovered KRAS mutation-reactive TCRs hunTR enables expansion of the Company’s hotspot mutation targeted TCR library HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc.

First patient achieved a confirmed partial response with 51.2% tumor regression with TCR-T cell persistence ongoing at 3 months post infusion Sleeping Beauty TCR-T cell therapy had a manageable safety profile with no dose limiting toxicities observed Data to be presented on Friday, September 30 at

HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development

First patient dosed achieved a confirmed objective partial response Second patient dosed at second dose level; cleared 28-day safety window Data to be presented on Friday, September 30 at 8:30am ET in a proffered presentation at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

HOUSTON, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it has been accepted to present a proffered talk at the CRI-ENCI-AACR Sixth International Cancer

Advancing TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; plan to present early data in 3Q 2022 at a scientific conference; moving ahead with second dose level Extended Cooperative Research and Development Agreement for development of